Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease

Summary Background Liver disease impacts on hepatic synthesis of lipoproteins and lipogenesis but data on dyslipidemia during disease progression are limited. We assessed the patterns of dyslipidemia in (i) different liver disease etiologies and discriminated (ii) non-advanced (non-ACLD) from advanc...

Full description

Saved in:
Bibliographic Details
Published in:Wiener Klinische Wochenschrift 2019-09, Vol.131 (17-18), p.395-403
Main Authors: Unger, Lukas W., Forstner, Bernadette, Schneglberger, Stephan, Muckenhuber, Moritz, Eigenbauer, Ernst, Scheiner, Bernhard, Mandorfer, Mattias, Trauner, Michael, Reiberger, Thomas
Format: Article
Language:English
Subjects:
Endocrinology
Gastroenterology
Internal Medicine
Medicine
Medicine & Public Health
Original
Original Article
Pneumology/Respiratory System
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Liver disease impacts on hepatic synthesis of lipoproteins and lipogenesis but data on dyslipidemia during disease progression are limited. We assessed the patterns of dyslipidemia in (i) different liver disease etiologies and discriminated (ii) non-advanced (non-ACLD) from advanced chronic liver disease (ACLD) as it is unclear how progression to ACLD impacts on dyslipidemia-associated cardiovascular risk. Methods Patients with alcoholic liver disease ( n  = 121), hepatitis C ( n  = 1438), hepatitis B ( n  = 384), metabolic/fatty liver disease ( n  = 532), cholestatic liver disease ( n  = 119), and autoimmune hepatitis ( n  = 114) were included. Liver stiffness ≥15 kPa defined ACLD. Dyslipidemia was defined as total cholesterol >200 mg/dL, low-density lipoprotein (LDL)-cholesterol >130 mg/dL and triglycerides >200 mg/dL. Results Across all etiologies, total cholesterol levels were significantly lower in ACLD, when compared to non-ACLD. Accordingly, LDL-cholesterol levels were significantly lower in ACLD due to hepatitis C, hepatitis B, metabolic/fatty liver disease and autoimmune hepatitis. Triglyceride levels did not differ due to disease severity in any etiology. Despite lower total and LDL cholesterol levels in ACLD, etiology-specific dyslipidemia patterns remained similar to non-ACLD. Contrary to this “improved” lipid status in ACLD, cardiovascular comorbidities were more prevalent in ACLD: arterial hypertension was present in 26.6% of non-ACLD and in 55.4% of ACLD patients ( p  
ISSN:0043-5325
1613-7671
DOI:10.1007/s00508-019-01544-5